直接抗病毒药物与肝癌早期复发风险：小题大做。 - Suppr

Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.

作者信息

Cammà Calogero, Cabibbo Giuseppe, Craxì Antonio

机构信息

Section of Gastroenterology, Biomedical Department of Internal and Specialized Medicine (Di.Bi.M.I.S.), University of Palermo, Italy.

出版信息

J Hepatol. 2016 Oct;65(4):861-862. doi: 10.1016/j.jhep.2016.04.033. Epub 2016 May 30.

DOI:10.1016/j.jhep.2016.04.033

PMID:27255578

Abstract

摘要

相似文献

Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.

J Hepatol. 2016 Oct;65(4):861-862. doi: 10.1016/j.jhep.2016.04.033. Epub 2016 May 30.

Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".

J Hepatol. 2016 Oct;65(4):864-865. doi: 10.1016/j.jhep.2016.05.036. Epub 2016 May 30.

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.

Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?

Gastroenterology. 2019 May;156(6):1558-1560. doi: 10.1053/j.gastro.2019.03.027. Epub 2019 Mar 26.

Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

J Hepatol. 2017 Jan;66(1):236-237. doi: 10.1016/j.jhep.2016.08.016. Epub 2016 Aug 31.

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Aliment Pharmacol Ther. 2017 Oct;46(7):688-695. doi: 10.1111/apt.14256. Epub 2017 Aug 9.

Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.

Ann Surg. 2015 Jan;261(1):56-66. doi: 10.1097/SLA.0000000000000858.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

引用本文的文献

CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy.

Afr Health Sci. 2023 Mar;23(1):198-212. doi: 10.4314/ahs.v23i1.22.

Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis.

Viruses. 2022 Dec 11;14(12):2762. doi: 10.3390/v14122762.

Remaining clinical issues in hepatitis C treatment.

Can Liver J. 2018 Jul 17;1(2):66-77. doi: 10.3138/canlivj.1.2.006. eCollection 2018 Spring.

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.

Transl Cancer Res. 2019 Apr;8(Suppl 3):S223-S232. doi: 10.21037/tcr.2019.04.01.

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis.

J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551.

Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.

Liver Cancer. 2020 Jun;9(3):261-274. doi: 10.1159/000504889. Epub 2020 Jan 7.

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.

Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351.

Independent risk factors for disease recurrence after surgery in patients with hepatitis B virus-related hepatocellular carcinoma ≤3 cm in diameter.

Gastroenterol Rep (Oxf). 2019 Aug;7(4):250-257. doi: 10.1093/gastro/goz009. Epub 2019 Mar 30.

Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.

Braz J Med Biol Res. 2019;52(8):e8519. doi: 10.1590/1414-431X20198519. Epub 2019 Aug 5.

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review.

J Adv Res. 2019 Mar 7;17:43-48. doi: 10.1016/j.jare.2019.03.001. eCollection 2019 May.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献